Improve Human Health to Preserve Patients’ Dignity

Leading new drug development for genitourinary tumors & other related diseases

Highlights

Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Treatment Areas

Bladder Cancer

Lack of oral therapy for non-muscle invasive bladder cancer (NMIBC) patients with improved patient compliance and less adverse effects from intravesical administration.

Precancerous Cervical Dysplasia

In urgent need of safe and effective options for patients with cervical precancerous lesions, currently treated by traditional surgical methods.

Global Partnership

News & Updates

Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch

Asieris’ Subsidiary Baylink Biosciences to Present Two Research Achievements at the 2025 American Association for Cancer Research Annual Meeting

Asieris’ Research Achievements Selected for Presentation at the 2025 American Association for Cancer Research Annual Meeting

Asieris’ APL-2302 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors

February 14, 2025

Asieris Presents Phase II Clinical Study Results of APL-1202 in Combined with PD-1 Inhibitor Tislelizumab as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer at 2025 ASCO-GU

January 24, 2025

Asieris Selected as the Top 10 Exhibitors with Communication Influence” in the Innovation Incubation Special Section of the 7th CIIE

Technology Platform